Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4821188 | 0.87 | PARP1 (0.58) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL5670690 | 0.84 | PARP1 (0.55) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL26472774 | 0.82 | PARP1 (0.57) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL5670684 | 0.82 | HSD17B10 (0.53) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL3641415 | 0.81 | PARP1 (0.56) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL5670577 | 0.80 | L3MBTL1 (0.58) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL7551218 | 0.80 | KMT2A (0.47) | PARP1ALDH1A1HSD17B10MAPK1GAA | |
| SCHEMBL5670687 | 0.80 | ALDH1A1 (0.56) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL5671330 | 0.80 | PARP1 (0.54) | PARP1ALDH1A1HSD17B10MAPK1HPGD | |
| SCHEMBL26123017 | 0.80 | ALDH1A1 (0.56) | PARP1ALDH1A1HSD17B10MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | claimed |
| US-20240374607-A1 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-11-14 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-4076459-A1 | PRMT5 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-110840847-B | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | 沃泰克斯药物股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-7842686-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842686-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842686-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2049532-B1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMA (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2049532-B1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMA (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2049532-A1 | CGRP RECEPTOR ANTAGONISTS | Vertex Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008011190-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011190-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-0980362-B1 | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICAMENTS | SCHERING AG (DE) | 2006-08-16 | — | — | EP | disclosed |
| US-6191127-B1 | ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
| EP-0980362-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050372-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE IN MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-11-12 | — | — | WO | disclosed |
| EP-0120589-B1 | IMIDAZO-HETEROCYCLIC COMPOUNDS, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-4621084-A | CARDIOTONIC, ANTIULCER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0120589-A1 | Imidazo-heterocyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374607-A1 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | HMGCR, OSBP, OSBPL3 | PARP1 4509/4885ALDH1A1 1169/4885HSD17B10 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.